What are the specific side effects of Ensifentrine?

Ohtuvayre (Ensifentrine) - Ensefentine/Ensifentrine inhalation suspension is a new type of inhaled drug, mainly used to treat chronic airway inflammatory diseases such as chronic obstructive pulmonary disease (COPD). It is a dual-mechanism drug that combines the dual effects of phosphodiesterase type 3 (PDE3) and phosphodiesterase type 4 (PDE4) inhibitors. This mechanism not only dilates the bronchi, but also has anti-inflammatory effects, so it has attracted clinical attention.

However, like other long-term inhaled treatment drugs for chronic diseases, exefantine may also cause a series of side effects. Especially in high doses, long-term use or in special groups, more attention should be paid to its adverse reaction characteristics. Common adverse reactions include oropharyngeal discomfort, hoarseness, throat irritation, dry cough, etc., which are mainly related to the inhalation administration itself. Such local reactions are usually mild and reversible, and most of them can resolve themselves after stopping the drug.

In addition, some patients may experience mild systemic reactions such as headache, nausea, and abnormal taste, which may be related to mild reactions in the central nervous system related to PDE4 inhibition. Some individuals may experience symptoms such as increased heart rate and mild chest tightness. Especially when combined with other bronchodilator treatments, attention should be paid to the additive effects of the drug.

In safety observations, exefentine has been shown to be better tolerated than traditionalPDE4 inhibitors, especially with fewer gastrointestinal reactions, but close observation is still recommended in the early stages of treatment. Special groups, such as elderly patients or those with abnormal cardiopulmonary function, are more likely to experience hypotension, dizziness and other reactions after taking the drug, because the PDE3 mechanism may cause mild vasodilation. In addition, similar to other inhaled drugs, bronchospasm reactions are rare but require vigilance, especially when inhaling for the first time, so the initial administration should be carried out under guidance.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html